Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Richard Simon, NCI’s visionary biostatistician, dies at 80
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- NCI: Cancer center communicators are key to the success of the National Cancer Plan
- As House prepares cuts for NIH, Rathmell urges Senate to protect funding in FY25
- Are we focused on the wrong risk type in genetic screening?
Breast cancer screening study shows new paths to population screening